- Home
- XAIR vs COCP Comparison
XAIR vs COCP Comparison
Compare XAIR & COCP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- XAIR
- COCP
- Stock Information
- Founded
- XAIR 2011
- COCP 2006
- Country
- XAIR United States
- COCP United States
- Employees
- XAIR N/A
- COCP N/A
- Industry
- XAIR Medical/Dental Instruments
- COCP Biotechnology: Pharmaceutical Preparations
- Sector
- XAIR Health Care
- COCP Health Care
- Exchange
- XAIR Nasdaq
- COCP Nasdaq
- Market Cap
- XAIR 17.0M
- COCP 15.4M
- IPO Year
- XAIR N/A
- COCP N/A
- Fundamental
- Price
- XAIR $2.43
- COCP $1.58
- Analyst Decision
- XAIR Strong Buy
- COCP Strong Buy
- Analyst Count
- XAIR 1
- COCP 1
- Target Price
- XAIR $11.00
- COCP $6.00
- AVG Volume (30 Days)
- XAIR 8.8M
- COCP 4.1M
- Earning Date
- XAIR 11-10-2025
- COCP 11-12-2025
- Dividend Yield
- XAIR N/A
- COCP N/A
- EPS Growth
- XAIR N/A
- COCP N/A
- EPS
- XAIR N/A
- COCP N/A
- Revenue
- XAIR $4,782,000.00
- COCP N/A
- Revenue This Year
- XAIR $265.24
- COCP N/A
- Revenue Next Year
- XAIR $136.17
- COCP N/A
- P/E Ratio
- XAIR N/A
- COCP N/A
- Revenue Growth
- XAIR 168.20
- COCP N/A
- 52 Week Low
- XAIR $2.02
- COCP $1.12
- 52 Week High
- XAIR $13.52
- COCP $3.26
- Technical
- Relative Strength Index (RSI)
- XAIR 48.32
- COCP 53.58
- Support Level
- XAIR $2.13
- COCP $1.37
- Resistance Level
- XAIR $4.78
- COCP $1.58
- Average True Range (ATR)
- XAIR 0.32
- COCP 0.16
- MACD
- XAIR 0.05
- COCP 0.00
- Stochastic Oscillator
- XAIR 11.82
- COCP 16.15
About XAIR Beyond Air Inc.
Beyond Air Inc is a commercial-stage medical device and biopharmaceutical company that develops a Nitric Oxide (NO) Generator and Delivery System that uses NO generated from ambient air and delivers precise amounts of NO to the lungs for the potential treatment of respiratory and other diseases. The firm is applying its therapeutic expertise to develop treatments for pulmonary hypertension, in addition to treatments for lower respiratory tract infections.
About COCP Cocrystal Pharma Inc.
Cocrystal Pharma Inc is a biotechnology company discovering and developing novel antiviral therapeutics that target the replication machinery of influenza viruses, hepatitis C viruses, and noroviruses. It employs structure-based technologies and Nobel Prize-winning expertise to create first and in-class antiviral drugs. It is developing CC-31244, an investigational, oral, broad-spectrum replication inhibitor called a non-nucleoside inhibitor (NNI).